Frontida Biopharm Leadership

Dr. Song Li founded Frontage Laboratories in 2001 with the ambition of building a client-focused organization to help solve the most complex drug development challenges. Prior to Frontage, Dr. Li held management positions at Great Valley Pharmaceuticals and Wyeth. During this time, he led numerous projects related to the development of pharmaceutical products. Dr. Li has authored more than 15 scientific publications spanning a wide range of topics, including chiral separations, drug-protein interactions, pharmacokinetics, and analytical chemistry. Importantly, Dr. Li has been the recipient of numerous awards, most recently Healthcare CEO award from Philadelphia Alliance for Capital and Technologies, Ernst & Young Entrepreneur of the Year Award, the “Realizing the American Dream” award from the Pennsylvania Welcoming Society, and the Outstanding 50 Asian Americans in Business Award from the AABDC. Dr. Li earned a doctor of philosophy degree in analytical chemistry from McGill University and a bachelor of science degree in chemistry from Zhengzhou University in China.

Anthony Qu is a Chief Operating Officer at FRONTIDA BIOPHARM INC.

Renard Jackson is an EVP, CMO Operations at FRONTIDA BIOPHARM INC.

Puneet Sapra has over 20 years of industry experience via executive roles. His expertise is in commercial, operational, and strategic finance.

Expert in nucleosides and related compounds as well as drug discovery and development

Multi-year pharmaceutical/biotech industry experiences in drug discovery and development settings; discovered numerous leads, pushed leads to clinical studies; proven experimental, research, and managerial skills with outstanding scientific record of publications and patent inventions.

Accomplishment Brief

 Received his Ph. D. degree in synthetic organic chemistry at Brigham Young University, and completed his postdoctoral training at the University of Virginia.

 Has over 20 years of pharmaceutical experience at Ionis, Acea, and Valeant with a broad experience in medicinal, synthetic organic, combinatorial, and nucleoside chemistry.

 His teams developed combinatorial technology and established the largest nucleoside library.

 Has been working on hit generation, hit-to-lead, and optimization for antiviral and anticancer drug discovery by targeting kinase, microtubule, RdRp, RT, proteasome and others.

 Successfully pushed lead compounds from scratch to clinics for HIV, HCV, HBV, kinase and antimitotic drugs; Lead full range of anticancer and antiviral drug development up to IND approval.

 Authored or co-authored over 60 publications in leading journals, and co-invented over 40 patents.

|script type=\'text/javascript\' src=\'https://platform.linkedin.com/badges/js/profile.js\' async defer||/script|

|div class=\'LI-profile-badge\' data-version=\'v1\' data-size=\'medium\' data-locale=\'en_US\' data-type=\'horizontal\' data-theme=\'light\' data-vanity=\'haoyunan\'|Harry An|/a||/div|

Dr. Song Li founded Frontage Laboratories in 2001 with the ambition of building a client-focused organization to help solve the most complex drug development challenges. Prior to Frontage, Dr. Li held management positions at Great Valley Pharmaceuticals and Wyeth. During this time, he led numerous projects related to the development of pharmaceutical products. Dr. Li has authored more than 15 scientific publications spanning a wide range of topics, including chiral separations, drug-protein interactions, pharmacokinetics, and analytical chemistry. Importantly, Dr. Li has been the recipient of numerous awards, most recently Healthcare CEO award from Philadelphia Alliance for Capital and Technologies, Ernst & Young Entrepreneur of the Year Award, the “Realizing the American Dream” award from the Pennsylvania Welcoming Society, and the Outstanding 50 Asian Americans in Business Award from the AABDC. Dr. Li earned a doctor of philosophy degree in analytical chemistry from McGill University and a bachelor of science degree in chemistry from Zhengzhou University in China.

Dr. Song Li founded Frontage Laboratories in 2001 with the ambition of building a client-focused organization to help solve the most complex drug development challenges. Prior to Frontage, Dr. Li held management positions at Great Valley Pharmaceuticals and Wyeth. During this time, he led numerous projects related to the development of pharmaceutical products. Dr. Li has authored more than 15 scientific publications spanning a wide range of topics, including chiral separations, drug-protein interactions, pharmacokinetics, and analytical chemistry. Importantly, Dr. Li has been the recipient of numerous awards, most recently Healthcare CEO award from Philadelphia Alliance for Capital and Technologies, Ernst & Young Entrepreneur of the Year Award, the “Realizing the American Dream” award from the Pennsylvania Welcoming Society, and the Outstanding 50 Asian Americans in Business Award from the AABDC. Dr. Li earned a doctor of philosophy degree in analytical chemistry from McGill University and a bachelor of science degree in chemistry from Zhengzhou University in China.